InforCapital
News•

Omega Funds Closes $647M Life Sciences Fund VIII - InforCapital

Omega Funds raises $647M for Fund VIII to back life sciences firms in the US and Europe, surpassing its $600M target amid tough VC markets.

AM
Alvaro de la Maza

Partner at Aninver

Key Takeaways

  • Sector: Biotechnology & Life Sciences.
  • Geography: United States.

Analysis

Omega Funds, the international healthcare venture capital firm, has closed its eighth fund with a total of $647 million in commitments—surpassing its original $600 million target. The funding support came from both new and existing limited partners.Since its founding in 2004, Omega has raised approximately $2.5 billion and helped bring 52 commercialized products to market across multiple therapeutic areas, including oncology, immunology, rare diseases, medical devices, and precision medicine. Its portfolio has delivered 50 exits via M&A and 47 IPOs, including notable companies like SoniVie, Scorpion Therapeutics, Bicara Therapeutics, and Morphic Therapeutic.

Omega Funds is headquartered in Boston, Massachusetts, USA. While based in the United States, the firm operates internationally with a strong focus on investing in both U.S. and European life sciences companies.

Fund VIII will continue Omega’s strategy of investing in transformative life science companies across the U.S. and Europe, supporting teams from early venture stages through later financing rounds.

This closing occurs in a market where global venture fundraising in life sciences is seeing a rebound. According to Grant Thornton, while VC deal volume in Q1 2025 remains below pre-pandemic peaks, larger fund sizes and selective capital flows are returning to the sector.

Other significant life sciences VC fund closings in 2024–2025 include:

  • Sofinnova Partners raised approximately €1.2 billion (~$1.3B) for new biotech investments across Europe
  • Abingworth, backed by Carlyle, launched a $1.5 billion clinical trials fund focused on late-stage drug development deals
  • Dementia Discovery Fund closed its second fund at $269 million, reinforcing its status as the largest dementia-focused VC vehicle

Market trackers highlight that the bar to raise life sciences funds in 2025 remains high—managers with clear, differentiated theses and successful track records are best positioned, while nearly half of capital raised in Q1 2025 was concentrated among just a handful of top-tier firms.

With its oversubscribed close and continued commitment to therapeutic innovation, Omega Fund VIII underscores investor confidence in venture-backed health technology despite sector-wide volatility. The fund is now positioned to support the next generation of life-changing therapies and platform companies.